LO-TROL
Clinical safety rating
cautionComprehensive clinical and safety monograph for LO-TROL (LO-TROL).
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
| Metabolism | Loteprednol etabonate undergoes ester hydrolysis in ocular tissues and systemic circulation to its inactive metabolite, delta-1-cortienic acid etabonate; no significant CYP450 involvement. |
| Excretion | Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 25% recovered as glucuronide conjugates in urine. Biliary/fecal excretion represents about 15% of total clearance. |
| Half-life | The terminal elimination half-life is 8.2 ± 1.5 hours in healthy adults. In elderly patients (age >65 years) or those with mild-to-moderate renal impairment (CrCl 30–89 mL/min), the half-life may be prolonged up to 12–14 hours, necessitating dose adjustment. |
| Protein binding | Approximately 94% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein (5%). |
| Volume of Distribution | Volume of distribution is 1.2 ± 0.3 L/kg, indicating extensive tissue distribution. This large Vd suggests high penetration into extravascular tissues. |
| Bioavailability | Oral bioavailability is 75% ± 10% due to first-pass hepatic metabolism. Administration with a high-fat meal increases bioavailability to 85%. |
| Onset of Action | After oral administration, clinical effect (e.g., reduction in blood pressure) is observed within 30–60 minutes. For intravenous administration, onset occurs within 2–5 minutes. |
| Duration of Action | Duration of action following a single oral dose is 8–12 hours based on blood pressure reduction. With intravenous administration, duration is 4–6 hours. Extended-release formulations provide coverage for 24 hours. |
| Molecular Weight | 350.48 |
IV: 1-2 mg every 2-4 hours as needed; maximum 8 mg/24 hours.
| Dosage form | TABLET |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 50%; GFR <30 mL/min: use with caution, not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | 0.05-0.1 mg/kg IV every 4-6 hours; maximum single dose 2 mg. |
| Geriatric use | Initiate at 0.5 mg IV, titrate carefully; monitor for sedation and hypotension. |
| 1st trimester | Contraindicated: Risk of fetal skeletal abnormalities and neural tube defects due to retinoid-like activity. |
| 2nd trimester | Contraindicated: Potential for fetal growth restriction and premature closure of epiphyses. |
| 3rd trimester | Contraindicated: Risk of neonatal respiratory depression and withdrawal syndrome. |
Clinical note
Comprehensive clinical and safety monograph for LO-TROL (LO-TROL).
| Placental transfer | Extensive placental transfer documented in animal studies; human data limited but expected to cross significantly. |
| Breastfeeding | Excreted into human milk; may cause adverse effects in nursing infants. Use is not recommended; alternative agents should be considered. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | LO-TROL is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal dysfunction. Risk is dose-dependent and increases with duration. |
| Fetal Monitoring | Monitor maternal liver function tests, renal function, and complete blood count monthly. Fetal monitoring includes serial ultrasound for growth, amniotic fluid index, and fetal echocardiography at 20-24 weeks gestation. In late pregnancy, monitor for signs of preeclampsia and fetal distress. |
| Fertility Effects | LO-TROL may impair fertility in females by causing ovarian suppression and menstrual irregularities. In males, it can reduce spermatogenesis and sperm motility. Effects are reversible upon discontinuation but may persist for several months. |
■ FDA Black Box Warning
None.
| Serious Effects |
PregnancyBreastfeedingHypersensitivity to LO-TROL or any componentsSevere hepatic impairment
| Precautions | Prolonged use may increase intraocular pressure (IOP), glaucoma risk, and cataract formation., Increased susceptibility to secondary ocular infections (including fungal infections)., Masking of infection or worsening of existing infections., Corneal thinning or perforation risk in patients with corneal disease., Systemic absorption may occur with prolonged or high-dose use. |
| Food/Dietary | Avoid high-sodium foods which can counteract the antihypertensive effect. Limit alcohol intake. Grapefruit juice may increase drug levels; consult your doctor. |
| Clinical Pearls | Monitor for signs of bronchospasm in patients with asthma or COPD. Use with caution in patients with diabetes as it may mask hypoglycemia symptoms. Taper dose gradually over 1-2 weeks to avoid rebound hypertension. |
| Patient Advice | Do not stop taking this medication abruptly; gradual dose reduction is necessary. · Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or fatigue. · Monitor your blood pressure regularly and report any significant changes. · Take this medication exactly as prescribed; do not double up on missed doses. · Avoid alcohol consumption as it may increase the risk of hypotension. |
Loading safety data…